Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

HPV16 E7-Driven Epithelial Hyperplasia Promotes Impaired Antigen Presentation and Regulatory T-Cell Development.

Bashaw AA, Teoh SM, Tuong ZK, Leggatt GR, Frazer IH, Chandra J.

J Invest Dermatol. 2019 Jun 15. pii: S0022-202X(19)31758-0. doi: 10.1016/j.jid.2019.03.1162. [Epub ahead of print]

PMID:
31207230
2.

NKT Cell-Driven Enhancement of Antitumor Immunity Induced by Clec9a-Targeted Tailorable Nanoemulsion.

Lam PY, Kobayashi T, Soon M, Zeng B, Dolcetti R, Leggatt G, Thomas R, Mattarollo SR.

Cancer Immunol Res. 2019 Jun;7(6):952-962. doi: 10.1158/2326-6066.CIR-18-0650. Epub 2019 May 3.

PMID:
31053598
3.

Recruitment of Antigen Presenting Cells to Skin Draining Lymph Node From HPV16E7-Expressing Skin Requires E7-Rb Interaction.

Kuo P, Teoh SM, Tuong ZK, Leggatt GR, Mattarollo SR, Frazer IH.

Front Immunol. 2018 Dec 18;9:2896. doi: 10.3389/fimmu.2018.02896. eCollection 2018.

4.

The Role of CXCR3 and Its Chemokine Ligands in Skin Disease and Cancer.

Kuo PT, Zeng Z, Salim N, Mattarollo S, Wells JW, Leggatt GR.

Front Med (Lausanne). 2018 Sep 25;5:271. doi: 10.3389/fmed.2018.00271. eCollection 2018. Review.

5.

Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia.

Kerage D, Soon MSF, Doff BL, Kobayashi T, Nissen MD, Lam PY, Leggatt GR, Mattarollo SR.

Oncoimmunology. 2018 Jul 26;7(10):e1486952. doi: 10.1080/2162402X.2018.1486952. eCollection 2018.

6.

An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes.

Joseph SR, Gaffney D, Barry R, Hu L, Banushi B, Wells JW, Lambie D, Strutton G, Porceddu SV, Burmeister B, Leggatt GR, Schaider H, Dolcetti R, Frazer IH, Saunders NA, Foote M, Soyer HP, Simpson F.

J Invest Dermatol. 2019 Jan;139(1):213-223. doi: 10.1016/j.jid.2018.06.190. Epub 2018 Aug 2.

7.

Development of a polyclonal anti-dugong immunoglobulin G (IgG) antibody with evaluation of total plasma IgG in a living dugong (Dugong dugon) population.

Wong A, Lanyon JM, McKee SJ, Linedale R, Woolford L, Long T, Leggatt GR.

Vet Immunol Immunopathol. 2018 Jun;200:16-25. doi: 10.1016/j.vetimm.2018.04.003. Epub 2018 Apr 9.

PMID:
29776608
8.

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.

McKee SJ, Tuong ZK, Kobayashi T, Doff BL, Soon MS, Nissen M, Lam PY, Keane C, Vari F, Moi D, Mazzieri R, Leggatt G, Gandhi MK, Mattarollo SR.

Oncoimmunology. 2017 Dec 18;7(2):e1393599. doi: 10.1080/2162402X.2017.1393599. eCollection 2018.

9.

HPV16E7-Induced Hyperplasia Promotes CXCL9/10 Expression and Induces CXCR3+ T-Cell Migration to Skin.

Kuo P, Tuong ZK, Teoh SM, Frazer IH, Mattarollo SR, Leggatt GR.

J Invest Dermatol. 2018 Jun;138(6):1348-1359. doi: 10.1016/j.jid.2017.12.021. Epub 2017 Dec 23.

10.

Modulation of antigen presenting cell functions during chronic HPV infection.

Bashaw AA, Leggatt GR, Chandra J, Tuong ZK, Frazer IH.

Papillomavirus Res. 2017 Dec;4:58-65. doi: 10.1016/j.pvr.2017.08.002. Epub 2017 Aug 18. Review.

11.

Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity.

Bhat P, Leggatt G, Waterhouse N, Frazer IH.

Cell Death Dis. 2017 Jun 1;8(6):e2836. doi: 10.1038/cddis.2017.67.

12.

HPV16-E7-Specific Activated CD8 T Cells in E7 Transgenic Skin and Skin Grafts.

Jazayeri SD, Kuo PT, Leggatt GR, Frazer IH.

Front Immunol. 2017 May 4;8:524. doi: 10.3389/fimmu.2017.00524. eCollection 2017.

13.

Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.

Linedale R, Schmidt C, King BT, Ganko AG, Simpson F, Panizza BJ, Leggatt GR.

PLoS One. 2017 Apr 19;12(4):e0175755. doi: 10.1371/journal.pone.0175755. eCollection 2017.

14.

Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.

Rearden R, Sah A, Doff B, Kobayashi T, McKee SJ, Leggatt GR, Mattarollo SR.

Immunol Cell Biol. 2016 Jul;94(6):554-62. doi: 10.1038/icb.2016.9. Epub 2016 Jan 20.

PMID:
26786233
15.

Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread.

Chawla S, Warren TA, Wockner LF, Lambie DL, Brown IS, Martin TP, Khanna R, Leggatt GR, Panizza BJ.

Cancer Immunol Immunother. 2016 Feb;65(2):213-22. doi: 10.1007/s00262-015-1788-z. Epub 2016 Jan 12.

PMID:
26759008
16.

Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.

Gabrielli B, Bokhari F, Ranall MV, Oo ZY, Stevenson AJ, Wang W, Murrell M, Shaikh M, Fallaha S, Clarke D, Kelly M, Sedelies K, Christensen M, McKee S, Leggatt G, Leo P, Skalamera D, Soyer HP, Gonda TJ, McMillan NA.

Mol Cancer Ther. 2015 Dec;14(12):2753-61. doi: 10.1158/1535-7163.MCT-15-0506. Epub 2015 Oct 29.

17.

Langerhans cell homeostasis and activation is altered in hyperplastic human papillomavirus type 16 E7 expressing epidermis.

Abd Warif NM, Stoitzner P, Leggatt GR, Mattarollo SR, Frazer IH, Hibma MH.

PLoS One. 2015 May 18;10(5):e0127155. doi: 10.1371/journal.pone.0127155. eCollection 2015.

18.

NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Kobayashi T, Doff BL, Rearden RC, Leggatt GR, Mattarollo SR.

Oncoimmunology. 2015 Jan 7;4(3):e990793. eCollection 2015 Mar.

19.

Recent progress in vaccination against human papillomavirus-mediated cervical cancer.

McKee SJ, Bergot AS, Leggatt GR.

Rev Med Virol. 2015 Mar;25 Suppl 1:54-71. doi: 10.1002/rmv.1824. Review.

PMID:
25752816
20.

HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells.

Bergot AS, Ford N, Leggatt GR, Wells JW, Frazer IH, Grimbaldeston MA.

PLoS Pathog. 2014 Oct 23;10(10):e1004466. doi: 10.1371/journal.ppat.1004466. eCollection 2014 Oct.

21.

The kinematics of cytotoxic lymphocytes influence their ability to kill target cells.

Bhat P, Leggatt G, Matthaei KI, Frazer IH.

PLoS One. 2014 May 6;9(5):e95248. doi: 10.1371/journal.pone.0095248. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e101381.

22.

Immunosuppressive roles of natural killer T (NKT) cells in the skin.

McKee SJ, Mattarollo SR, Leggatt GR.

J Leukoc Biol. 2014 Jul;96(1):49-54. doi: 10.1189/jlb.4RU0114-001R. Epub 2014 May 5. Review.

PMID:
24799605
23.

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses.

Leggatt GR.

Vaccines (Basel). 2014 Jul 2;2(3):537-48. doi: 10.3390/vaccines2030537. Review.

24.

Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7.

Mittal D, Kassianos AJ, Tran LS, Bergot AS, Gosmann C, Hofmann J, Blumenthal A, Leggatt GR, Frazer IH.

J Invest Dermatol. 2013 Dec;133(12):2686-2694. doi: 10.1038/jid.2013.222. Epub 2013 May 7.

25.

Expression of a single, viral oncoprotein in skin epithelium is sufficient to recruit lymphocytes.

Choyce A, Yong M, Narayan S, Mattarollo SR, Liem A, Lambert PF, Frazer IH, Leggatt GR.

PLoS One. 2013;8(2):e57798. doi: 10.1371/journal.pone.0057798. Epub 2013 Feb 26.

26.

A combination of local inflammation and central memory T cells potentiates immunotherapy in the skin.

Fiorenza S, Kenna TJ, Comerford I, McColl S, Steptoe RJ, Leggatt GR, Frazer IH.

J Immunol. 2012 Dec 15;189(12):5622-31. doi: 10.4049/jimmunol.1200709. Epub 2012 Nov 9.

27.

Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice.

Heng TS, Reiseger JJ, Fletcher AL, Leggatt GR, White OJ, Vlahos K, Frazer IH, Turner SJ, Boyd RL.

PLoS One. 2012;7(8):e42677. doi: 10.1371/journal.pone.0042677. Epub 2012 Aug 3.

28.

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A.

EMBO Mol Med. 2012 Aug;4(8):675-84. doi: 10.1002/emmm.201101131. Epub 2012 Jun 25. Review.

29.

γδ T cells augment rejection of skin grafts by enhancing cross-priming of CD8 T cells to skin-derived antigen.

Rahimpour A, Mattarollo SR, Yong M, Leggatt GR, Steptoe RJ, Frazer IH.

J Invest Dermatol. 2012 Jun;132(6):1656-64. doi: 10.1038/jid.2012.16. Epub 2012 Feb 23.

30.

Histone deacetylase inhibitors in the generation of the anti-tumour immune response.

Leggatt GR, Gabrielli B.

Immunol Cell Biol. 2012 Jan;90(1):33-8. doi: 10.1038/icb.2011.94. Epub 2011 Nov 8. Review.

PMID:
22064708
31.

NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins.

Mattarollo SR, Yong M, Gosmann C, Choyce A, Chan D, Leggatt GR, Frazer IH.

J Immunol. 2011 Aug 15;187(4):1601-8. doi: 10.4049/jimmunol.1100756. Epub 2011 Jul 8.

32.

Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocyte antigen processing and T-cell lysis.

Zhou F, Leggatt GR, Frazer IH.

FEBS J. 2011 Apr;278(6):955-63. doi: 10.1111/j.1742-4658.2011.08011.x. Epub 2011 Feb 5.

33.

Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.

Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR.

Immunol Rev. 2011 Jan;239(1):85-98. doi: 10.1111/j.1600-065X.2010.00966.x. Review.

PMID:
21198666
34.

Prevention and treatment of papillomavirus-related cancers through immunization.

Frazer IH, Leggatt GR, Mattarollo SR.

Annu Rev Immunol. 2011;29:111-38. doi: 10.1146/annurev-immunol-031210-101308. Review.

PMID:
21166538
35.

IL-1 signalling determines the fate of skin grafts expressing non-self protein in keratinocytes.

Hadis U, Leggatt GR, Thomas R, Frazer IH, Kovacs EM.

Exp Dermatol. 2010 Aug;19(8):723-9. doi: 10.1111/j.1600-0625.2010.01092.x.

36.

Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen.

Mattarollo SR, Yong M, Tan L, Frazer IH, Leggatt GR.

J Immunol. 2010 May 15;184(10):5663-9. doi: 10.4049/jimmunol.0903730. Epub 2010 Apr 21.

37.

Antigen-specific CD4 cells assist CD8 T-effector cells in eliminating keratinocytes.

Broom JK, Lew AM, Azukizawa H, Kenna TJ, Leggatt GR, Frazer IH.

J Invest Dermatol. 2010 Jun;130(6):1581-9. doi: 10.1038/jid.2010.17. Epub 2010 Feb 11.

38.

Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production.

Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH.

J Immunol. 2010 Feb 1;184(3):1242-50. doi: 10.4049/jimmunol.0902191. Epub 2009 Dec 18.

39.

Enhanced tumor growth in the NaS1 sulfate transporter null mouse.

Dawson PA, Choyce A, Chuang C, Whitelock J, Markovich D, Leggatt GR.

Cancer Sci. 2010 Feb;101(2):369-73. doi: 10.1111/j.1349-7006.2009.01399.x. Epub 2009 Oct 12.

40.

Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis.

Zhou F, Frazer IH, Leggatt GR.

Exp Dermatol. 2009 Dec;18(12):1053-9. doi: 10.1111/j.1600-0625.2009.00907.x.

PMID:
19601980
41.

IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host.

Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer IH.

J Immunol. 2009 Jul 1;183(1):51-8. doi: 10.4049/jimmunol.0802047. Epub 2009 Jun 17.

42.

Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses.

Gu W, Cochrane M, Leggatt GR, Payne E, Choyce A, Zhou F, Tindle R, McMillan NA.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8314-9. doi: 10.1073/pnas.0812085106. Epub 2009 May 4.

43.

Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells.

Narayan S, Choyce A, Linedale R, Saunders NA, Dahler A, Chan E, Fernando GJ, Frazer IH, Leggatt GR.

Eur J Immunol. 2009 Feb;39(2):481-90. doi: 10.1002/eji.200838527.

44.

TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes.

Zhong J, Hadis U, De Kluyver R, Leggatt GR, Fernando GJ, Frazer IH.

Eur J Immunol. 2008 Jan;38(1):73-81.

45.

HPV vaccines: the beginning of the end for cervical cancer.

Leggatt GR, Frazer IH.

Curr Opin Immunol. 2007 Apr;19(2):232-8. Epub 2007 Feb 12. Review.

PMID:
17293100
46.
47.

Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host.

Liu XS, Dyer J, Leggatt GR, Fernando GJ, Zhong J, Thomas R, Frazer IH.

J Immunol. 2006 Sep 1;177(5):2873-9.

48.

Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes.

Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, McMillan NA.

Cancer Gene Ther. 2006 Nov;13(11):1023-32. Epub 2006 Jun 30.

PMID:
16810314
49.

RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.

Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, McMillan NA.

Mol Pharmacol. 2005 Nov;68(5):1311-9. Epub 2005 Aug 24.

PMID:
16120770
50.

Human growth hormone presented by K14hGH-transgenic skin grafts induces a strong immune response but no graft rejection.

Zhong J, Matsumoto K, De Kluyver R, Fernando GJ, Leggatt GR, Frazer IH.

Immunol Cell Biol. 2004 Dec;82(6):577-86.

PMID:
15550115

Supplemental Content

Loading ...
Support Center